

Supporting Information:

A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy

Paul Hoppenz,[†] Sylvia Els-Heindl,[†] Martin Kellert,[‡] Robert Kuhnert,[‡] Stefan Saretz,[‡] Hans-Georg Lerchen,[§] Johannes Köbberling,[§] Bernd Riedl,[§] Evamarie Hey-Hawkins,[‡] and Annette G. Beck-Sickinger^{,†}*

[†]Institute of Biochemistry, Faculty of Life Sciences, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany

[‡]Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany

[§]Bayer AG, Aprather Weg 18A, Wuppertal, Germany

*corresponding author: Annette G. Beck-Sickinger; E-mail: abeck-sickinger@uni-leipzig.de.

Telephone: +49 341 97-36900. Telefax: +49 341 97-36909.

Table of Content

Figure S1: RP-HPLC pure analytics of all synthesized peptide conjugates 1-8	S2
Figure S2: RP-HPLC pure analytics of all synthesized peptide conjugates 9-11, 2T, 10T and 11T .	S3
Figure S3: Detailed characterization of conjugate 4 by mass spectrometry and RP-HPLC.	S4
Figure S4: <i>In vitro</i> characterization of mono and bis-Gal-cluster conjugates 3-5	S5
Figure S5: Kinetic solubility assay investigating the aggregation properties of conjugate 2 and 6-10 .	S6




Figure S1: RP-HPLC pure analytics of peptide **1-8** using a Phenomenex Jupiter® 4u Proteo C12 90 Å column and applying linear gradients of eluent B (ACN + 0.08 % TFA (v/v)) in eluent A (H₂O + 0.1 % TFA (v/v)) over 40 min.




Figure S2: RP-HPLC pure analytics of peptide **9-11**, **2T**, **10T** and **11T** using a Phenomenex Jupiter® 4u Proteo C12 90 Å column and applying linear gradients of eluent B (ACN + 0.08 % TFA (v/v)) in eluent A (H₂O + 0.1 % TFA (v/v)) over 40 min.




Figure S3: Detailed characterization of conjugate 4 by mass spectrometry and RP-HPLC. (A) Pure RP-HPLC chromatogram of conjugate 4 on a Kinetex XB-C₁₈ column (Phenomenex, C18, 5 μ m, 100 \AA) using a linear gradient of 20 % to 70 % (v/v) eluent B (0.08 % TFA in ACN) in eluent A (0.1 % TFA in water) in 40 min. (B) MALDI-ToF mass spectra of each separated peak obtained from RP-HPLC analysis of conjugate 4. (C) RP-HPLC analysis of each separated peak after indicated incubation times at room temperature using a Kinetex XB-C₁₈ column (Phenomenex, C18, 5 μ m, 100 \AA) and a linear gradient of 20 % to 70 % (v/v) eluent B (0.08 % TFA in ACN) in eluent A (0.1 % TFA in water) in 40 min.




Figure S4: *In vitro* characterization of mono and bis-Gal-cluster conjugates 3-5 (A) Concentration-response curves of conjugate **3-5** obtained from Ca^{2+} -mobilization assay using stably transfected HEK293_GRPR-tGFP cells. Data were normalized to Uni response (bottom value = 0 %, top value = 100 %) and the standard error of mean (SEM) is indicated at each data point, which represents the mean, obtained in at least two independent experiments, each performed in duplicate. (B) Receptor internalization studies of HEK293 cells stably expressing the GRPR fused to tGFP (green). Nuclei were stained with Hoechst33342 (blue) and cells were stimulated with 100 nM for 1 h at 37 °C. Scale bar = 10 μm




Figure S5: Kinetic solubility assay investigating the aggregation properties of conjugate 2 and 6-10.